Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095064 | 0.88 | P2RX7 (0.45) | P2RX7TGFBR1HTR2AHTR2C | |
| SCHEMBL2069845 | 0.82 | TGFBR1 (0.60) | TGFBR1CSNK1DCSNK1EGSK3BDYRK1A | |
| SCHEMBL25268913 | 0.76 | MAPK14 (0.55) | TGFBR1CSNK1DCSNK1EGSK3B | |
| SCHEMBL15340400 | 0.76 | TGFBR1 (0.55) | TGFBR1CSNK1DCSNK1EHTR2BHTR2A | |
| SCHEMBL5273467 | 0.76 | ADRB1 (0.30) | — | |
| SCHEMBL10095065 | 0.75 | HTR7 (0.39) | P2RX7TGFBR1HTR7HTR1AHTR2A | |
| SCHEMBL19495428 | 0.72 | TGFBR1 (0.48) | TGFBR1CSNK1DCSNK1EGSK3BDYRK1A | |
| SCHEMBL15830769 | 0.72 | TGFBR1 (0.48) | TGFBR1CSNK1DCSNK1EGSK3BDYRK1A | |
| SCHEMBL10095034 | 0.72 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL1203436 | 0.71 | GSK3B (0.56) | P2RX7TGFBR1GSK3BDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424867-B1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-2424867-B1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2424867-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | P2RX7 1/4885TGFBR1 873/4885CSNK1D 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.